Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | QDPR | P09417 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5022923 | 0.91 | EPHX2 (0.47) | SMN1; SMN2CYP1A2TDP1EPHX2EPHX1 | |
| SCHEMBL14996198 | 0.85 | — | — | |
| SCHEMBL6277604 | 0.85 | — | — | |
| SCHEMBL5017011 | 0.85 | — | — | |
| SCHEMBL90563 | 0.82 | CYP1A2 (0.48) | SMN1; SMN2CYP1A2TDP1EPHX2EPHX1 | |
| SCHEMBL329321 | 0.81 | CYP1A2 (0.52) | SMN1; SMN2CYP1A2TDP1EPHX2EPHX1 | |
| SCHEMBL15116670 | 0.80 | DPP4 (0.36) | SMN1; SMN2EPHX2EPHX1 | |
| Hydrochloric Acid SCHEMBL1132378 | 0.80 | GNAI3 (0.50) | SMN1; SMN2CYP1A2TDP1EPHX2EPHX1 | |
| SCHEMBL18711943 | 0.80 | L3MBTL3 (0.41) | SMN1; SMN2EPHX2EPHX1KDM4E | |
| SCHEMBL21325280 | 0.79 | CYP1A2 (0.50) | SMN1; SMN2CYP1A2TDP1EPHX2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200179376-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE | KYOWA KIRIN CO., LTD. (JP) | 2020-06-11 | — | — | US | claimed |
| US-20150352106-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE | KYOWA KIRIN CO., LTD. (JP) | 2015-12-10 | — | — | US | claimed |
| EP-2570411-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING KYNURENINE PRODUCTION INHIBITORY ACTIVITY | Kyowa Hakko Kirin Co., Ltd. (JP) | 2013-03-20 | — | — | EP | claimed |
| US-20130065905-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2013-03-14 | — | — | US | claimed |
| EP-4630410-A1 | POLQ INHIBITORS | Astrazeneca AB (SE) | 2025-10-15 | — | — | EP | disclosed |
| WO-2024121753-A1 | POLQ INHIBITORS | ASTRAZENECA AB (SE) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024102952-A1 | SOS1 INHIBITORS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024015251-A1 | INHIBITORS OF HPK1 AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230218612-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE | KYOWA KIRIN CO., LTD. (JP) | 2023-07-13 | — | — | US | disclosed |
| WO-2023288253-A1 | SMALL MOLECULES INHIBITORS OF CYCLIC GMP-AMP SYNTHASE (CGAS) | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2022089463-A1 | BCL-2 PROTEIN APOPTOSIS-INDUCING AGENT AND APPLICATION THEREOF | 杭州和正医药有限公司 | 2022-05-05 | — | — | WO | disclosed |
| WO-2008073451-A2 | BENZOIMIDAZOLE DERIVATIVES AS SIRTUIN (SIR) MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| US-20080070123-A1 | NONAQUEOUS ELECTROLYTE SOLUTION FOR SECONDARY BATTERY AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | SANYO ELECTRIC CO., LTD. (JP) | 2008-03-20 | — | — | US | disclosed |
| WO-2007019346-A1 | BENZOTHIAZOLES AND THIAZOLOPYRIDINES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007019344-A1 | IMIDAZO [2,1-B] THIAYOLE DERIVATIVES AS SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007019417-A1 | OXAZOLOPYRIDINE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007019416-A1 | BENZIMIDAZOLE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007019345-A1 | IMIDAZOPYRIDINE DERIVATIVES AS SIRTUIN MODULATING AGENTS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20060035155-A1 | Nonaqueous electrolyte solution for secondary battery and nonaqueous electrolyte secondary battery | SANYO ELECTRIC CO., LTD. (JP) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200179376-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE | KYNU, KMO, IDO1 | SMN1; SMN2 4325/4885CYP1A2 1060/4885TDP1 4074/4885 |
| US-20150352106-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE | KYNU, KMO, IDO1 | SMN1; SMN2 4325/4885CYP1A2 1060/4885TDP1 4074/4885 |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | IKZF1, IKZF3, IKZF2 | SMN1; SMN2 1860/4885CYP1A2 3530/4885TDP1 1177/4885 |
| US-20230218612-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE | KYNU, KMO, IDO1 | SMN1; SMN2 4325/4885CYP1A2 1060/4885TDP1 4074/4885 |
| US-20130065905-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE | KYNU, KMO, IDO1 | SMN1; SMN2 4284/4885CYP1A2 1044/4885TDP1 3958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.